Leerink analyst Mani Foroohar maintained a Market Perform rating and $46 price target on Ionis Pharmaceuticals following the FDA approval of approved Wainua in hereditary transthyretin amyloidosis polyneuropathy, which the analyst said was already “largely baked into the price” of the stock.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IONS:
- Ionis Stock (NASDAQ:IONS) Advances as FDA Approves its Nerve Drug
- Ionis Pharmaceuticals enters license agreement with Otsuka Pharmaceutical
- Citi says approval ‘likely’ for Ionis’ eplontersen ATTR-PN NDA
- Ionis Pharmaceuticals participates in a conference call with William Blair
- William Blair says buy these stocks for 2024
